12.73

0.47% -0.06

Pre-market: 13.55 0.82 +6.44%

Pliant Therapeutics Inc (PLRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pliant Therapeutics Inc stock is traded at $12.73, with a volume of 474.25K. It is down -0.47% in the last 24 hours and down -16.25% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Previous Close:

$12.79

Open:

$12.67

24h Volume:

474.25K

Relative Volume:

1.23

Market Cap:

$766.15M

Revenue:

$5.03M

Net Income/Loss:

$-185.41M

P/E Ratio:

-4.646

EPS:

-2.74

Net Cash Flow:

$-139.79M

1W Performance:

-7.55%

1M Performance:

-16.25%

6M Performance:

-15.81%

1Y Performance:

-11.35%

1-Day Range:

$12.22

$12.74

1-Week Range:

$11.76

$14.04

52-Week Range:

$10.22

$19.62

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name

Pliant Therapeutics Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

650-481-6770

Address

331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

166

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PLRX's Discussions on Twitter

Compare PLRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLRX	12.73	766.15M	5.03M	-185.41M	-139.79M	-2.74
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-23	Initiated	Canaccord Genuity	Buy
Apr-13-23	Initiated	Robert W. Baird	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-07-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Buy
Jul-20-22	Initiated	SVB Leerink	Outperform
May-25-22	Initiated	Cantor Fitzgerald	Overweight
Dec-10-21	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	RBC Capital Mkts	Outperform
Nov-03-21	Initiated	H.C. Wainwright	Buy
Apr-20-21	Initiated	BTIG Research	Buy
Apr-05-21	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Cowen	Outperform
Jun-29-20	Initiated	Needham	Buy
Jun-29-20	Initiated	Piper Sandler	Overweight

View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

Nov 18, 2024

Pliant Therapeutics Reports Increased Losses and Strategic Focus - TipRanks

Nov 18, 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire

Nov 18, 2024

Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com

Nov 15, 2024

First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Objective long/short (PLRX) Report - Stock Traders Daily

Nov 14, 2024

Nov 11, 2024

Pliant Therapeutics maintains stock target with Buy rating on clinical trial - Investing.com UK

Nov 11, 2024

Nov 08, 2024

Stifel maintains Buy on Pliant Therapeutics, target at $32 By Investing.com - Investing.com UK

Nov 08, 2024

HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat

Nov 08, 2024

Nov 07, 2024

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024

Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St

Nov 07, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat

Nov 07, 2024

Nov 06, 2024

Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times

Nov 06, 2024

Pliant Therapeutics to Present at Stifel 2024 Healthcare Conference | Key Leadership Insights | PLRX Stock News - StockTitan

Nov 06, 2024

Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Nov 03, 2024

Oct 21, 2024

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat

Oct 21, 2024

SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 21, 2024

Oct 17, 2024

Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia

Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire

Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance

Oct 17, 2024

Oct 15, 2024